NEC Baby Formula Marketing & Claimant Acquisition

The litigation landscape

The NEC baby formula litigation is consolidated in an MDL, reflecting the volume of claims and the shared factual questions around bovine-based preterm infant formula and its association with Necrotizing Enterocolitis in premature newborns. The two primary defendants — Abbott Laboratories, maker of Similac, and Mead Johnson, maker of Enfamil — are among the most recognized infant formula brands in the United States, which means claimants are likely to remember exactly which product was used in the NICU and can often confirm administration through medical records.

NEC is a devastating gastrointestinal condition that primarily affects premature infants, and the NICU setting creates a documented, traceable chain of product use that supports intake qualification. The MDL posture signals that this litigation has reached a stage where plaintiff firms are actively building dockets, making now an appropriate window for sustained paid acquisition before the landscape becomes more competitive.

Who a campaign targets

• Premature infant diagnosis: Campaigns are built around families of infants born prematurely — this is the core qualifying characteristic and the foundation of every intake conversation.
• NEC diagnosis confirmed: The target claimant has a documented Necrotizing Enterocolitis diagnosis, ideally supported by medical records from the NICU stay.
• Bovine-based formula administered in the NICU: The infant received Abbott Similac or Mead Johnson Enfamil formula during their neonatal intensive care unit stay — this product-exposure link is central to the claim and should be confirmed early in intake.
• Borderline profiles to screen carefully: Full-term infants and cases without NICU records present qualification challenges; intake teams should be briefed to flag these for attorney review rather than auto-qualifying or auto-rejecting.

How MTAA runs NEC Baby Formula campaigns

The creative strategy for NEC baby formula campaigns lives at the intersection of parental grief, institutional trust, and brand recognition. Parents who spent time in a NICU with a premature infant carry vivid memories of that experience — including which formula was used. Meta's targeting environment allows MTAA to reach parents in the appropriate age and life-stage demographics, and the Similac and Enfamil brand names function as immediate recognition triggers in ad copy and creative. The emotional weight of a NEC diagnosis means that when the right parent sees the right message, the connection is immediate; the creative challenge is framing that message with care and clarity rather than sensationalism.

On the intake side, the qualification criteria are concrete enough to support a structured pre-screen: prematurity, NICU admission, formula brand, and NEC diagnosis are all verifiable data points that a trained intake team can confirm efficiently. MTAA structures campaigns to drive volume at the top of the funnel while building in qualification checkpoints that protect your cost-per-signed metric. We manage creative rotation, audience segmentation, and compliance review so your team receives leads that are already pre-screened against the core criteria before they reach a case manager.